TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Attention Deficit Hyperactivity Disorder in Preschool-Age Children (PATS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Boys and girls who are:~* Between the ages of 3-5.5 years~* Qualified as having ADHD by our diagnostic evaluations and clinical staff~* Otherwise generally healthy~* Willing, and have parents that are willing, to attend all visits required by the study~* Enrolled in some type of day-program: day care, preschool, nursery school, kindergarten, for at least 2 half days/week~* In classrooms with teachers that are willing to participate by completing rating scale

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 5 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of plaque-type psoriasis with or without psoriatic arthritis (PsA) for at least 6 months~* Are candidates for phototherapy or systemic treatment of psoriasis~* Have screening laboratory test results within the study parameters~Exclusion Criteria:~* Currently have nonplaque forms of psoriasis~* Have used any therapeutic agent targeted at reducing interleukin-12 (IL-12) or interleukin-23 (IL-23), including but not limited to ustekinumab and briakinumab~* Received conventional systemic therapies or phototherapy within the last 4 weeks~* Received biologic therapies within the last 3 months

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Ustekinumab Half-standard Dosage (Type: EXPERIMENTAL): Participants will receive ustekinumab at half the standard dosage at Weeks 0, 4, 16, 28, and 40. In addition, all participants will receive a single SC dose of placebo at Week 12.
- Ustekinumab Standard Dosage (Type: EXPERIMENTAL): Participants will receive ustekinumab at the standard dosage at Weeks 0, 4, 16, 28, and 40. In addition, all participants will receive a single SC dose of placebo at Week 12.
- Placebo (Type: EXPERIMENTAL): Participants will receive matching placebo at Week 0 and 4, followed by ustekinumab at half-standard or standard dosage at Weeks 12, 16, 28, and 40.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Pigmented Skin Lesions With MelaFind(R) System

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The lesion is pigmented (i.e., melanin, keratin, blood)~* Clinical management of the lesion by the examining dermatologist is either biopsy of the lesion in toto, or 3-month follow-up of the lesion~* The diameter of the pigmented area is between 2 and 22 millimeters~* The lesion is accessible to the MelaFind hand-held imaging device~* The patient, or a legally authorized representative, has consented to participate in the study and has signed the Informed Consent Form~Exclusion Criteria:~* The patient has a known allergy to isopropyl alcohol~* The lesion has been previously biopsied, excised, or traumatized~* The skin is not intact (e.g., open sores, ulcers, bleeding)~* The lesion is within 1 cm of the eye~* The lesion is on mucosal surfaces (e.g., lips, genitals)~* The lesion is on palmar hands~* The lesion is on plantar feet~* The lesion is on or under nails~* The lesion is located on or in an area of visible scarring~* The lesion contains foreign matter (e.g., tattoo, splinter, marker)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Biopsied Pigmented Skin Lesions (Type: OTHER): Pigmented skin lesions for which clinical management was prospectively determined to be biopsy of the lesion in toto

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Late-Onset Treatment Study Extension Protocol

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must have completed protocol AGLU02704 (NCT00158600)~* Patient must provide signed, informed consent prior to performing any study-related procedures~* Patient (and patient's legal guardian if patient is under 18 years of age) must have the ability to comply with the clinical protocol~* A female patient of childbearing potential must have a negative pregnancy test at Baseline. (note: all female patients of childbearing potential and sexually mature males must use a medically accepted method of contraception throughout the study.)~Exclusion Criteria:~* The patient has a medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, would preclude treatment with alglucosidase alfa.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alglucosidase Alfa/Alglucosidase Alfa (Type: EXPERIMENTAL): Participants who received alglucosidase alfa during the double-blind study and, if they completed the double-blind study, continued that treatment during the extension study. Participants received an intravenous (IV) infusion of 20 mg/kg of alglucosidase alfa every other week (qow) until their participation in both the AGLU02704 (NCT00158600) and AGLU03206 studies combined equaled a minimum of 104 weeks.
- Placebo/Alglucosidase Alfa (Type: EXPERIMENTAL): Participants given placebo during the double-blind study, completed the double-blind study (study AGLU02704, NCT00158600), and qualified to continue into the extension study on alglucosidase alfa. Participants received an intravenous (IV) infusion of 20 mg/kg of alglucosidase alfa every other week (qow) for up to 52 weeks. Only the alglucosidase alfa treatment experience is included in this extension study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Relapsing multiple sclerosis,~* Two relapses in prior 2 years or one relapse in prior year.~Exclusion Criteria:~* Clinically relevant cardiovascular, hepatic, neurological, endocrine or other major systemic disease,~* Significantly impaired bone marrow function or, significant anemia, leukopenia or thrombocytopenia,~* Pregnant or nursing woman,~* Alcohol or drug abuse,~* Prior or concomitant use of cladribine, mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate,~* Human immunodeficiency virus (HIV) positive,~* Any known condition or circumstance that would prevent, in the investigator's opinion, compliance or completion of the study.~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Teriflunomide 7 mg / 14 mg (Type: EXPERIMENTAL): Core treatment period: Teriflunomide 7 mg once daily. Extension treatment period: Teriflunomide 14 mg once daily.
- Teriflunomide 14 mg / 14 mg (Type: EXPERIMENTAL): Core treatment period: Teriflunomide 14 mg once daily. Extension treatment period: Teriflunomide 14 mg once daily.
- Placebo / Teriflunomide 14 mg (Type: PLACEBO_COMPARATOR): Core treatment period: Placebo (for teriflunomide) once daily. Extension treatment period: Teriflunomide 14 mg once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single-Dose Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with SMA Type 1 as determined by diagnosis of SMA based on gene mutation analysis with biallelic SMN1 mutations (deletion or point mutations) and one or two copies of SMN2 \[inclusive of the known SMN2 gene modifier mutation (c.859G\>C)\]~* Patients must be \< 6 months (\< 180 days) of age at the time of onasemnogene abeparvovec-xioi infusion~* Patients must have a swallowing evaluation test performed prior to administration of gene replacement therapy~Exclusion Criteria:~* Previous, planned or expected scoliosis repair surgery/procedure prior to 18 months of age~* Use of invasive ventilatory support (tracheotomy with positive pressure) or pulse oximetry \< 95% saturation at screening~* Use or requirement of non-invasive ventilatory support for 12 or more hours daily in the two weeks prior to dosing~* Patient with signs of aspiration based on a swallowing test or whose weight-for-age falls below the 3rd percentile based on World Health Organization (WHO) Child Growth Standards and unwilling to use an alternative method to oral feeding~* Participation in recent SMA treatment clinical trial (with the exception of observational cohort studies or non-interventional studies) or receipt of an investigational or commercial compound, product or therapy administered with the intent to treat SMA (eg, nusinersen, valproic acid,) at any time prior to screening for this trial.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 6 Months
- Healthy Volunteers: f

Study Arms:
- Onasemnogene Abeparvovec-xioi (Type: EXPERIMENTAL): Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Perioperative Administration of Pregabalin for Pain After Robot-assisted Endoscopic Thyroidectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. American Society of Anesthesia physical status class I \& II~2. Age ≥ 20 and ≤ 65 years~3. Robot- assisted endoscopic thyroidectomy~Exclusion Criteria:~1. Known or suspected allergy, sensitivity, or contraindication to pregabalin or any of the standardized medications~2. Body mass index ≥ 40 kg/m2~3. History of seizure disorder~4. Current therapy with pregabalin, gabapentin, or any opioid~5. Any other physical or psychiatric condition which may impair their ability to cooperate with post-operative study data collection~6. Insulin-dependent diabetes mellitus~7. Renal insufficiency (estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m2)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Patients receive oral Placebo 150 mg 1 hour prior to surgery, and 12 hours later
- Pregabalin (Type: EXPERIMENTAL): Patients receive oral pregabalin 150 mg 1 hour prior to surgery, and 12 hours later

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous High Dose Iron in Blood Donors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age ≥18 years and ≤ 65 years~* ferritin ≤ 30 ng/ml~* fulfilment of the strict criteria for blood donation~Exclusion Criteria:~* hemochromatosis~* active infection~* pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Oral Iron (Type: ACTIVE_COMPARATOR): oral iron in a corresponding dose of 10g (assuming an absorption of 10%, 100 capsules a 100mg iron each) taken over 8-12 weeks
- Intravenous high dose iron (Type: EXPERIMENTAL): high dose intravenous iron (ferric carboxymaltose, 1000mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Non-inferiority Study With Two Treatment Arms Eszopiclone 3 mg Versus Zopiclone 7.5 mg - for the Treatment of Insomnia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Sign the informed consent form for the study;~* Be ≥ 20 to ≥ 64 years old;~* Have diagnosis of symptomatic primary insomnia for at least 3 months;~* Have polysomnography conducted at least 90 days before the inclusion in the study with sleep time less than 6.5 hours and sleep latency ≥ 20 minutes;~* Be able not to take any insomnia medication for 14 days before randomization to the study (washout period).~Exclusion Criteria:~* Diagnosis of other sleep disorder by polysomnography conducted 90 days before the inclusion in the study;~* Use of any medication affecting the sleep, such as psychotropic, hypnotic or antihistamine agents for at least 15 days before the inclusion in the study;~* Use of any herbal supplement for insomnia or melatonin during the 14 days before entering the study;~* Current use of liver metabolized medication, especially those metabolized through the cytochrome P450 enzyme complex, especially through the CYP3A4 and/or CYP2E1 routes;~* History of daily use of alcohol beverages in quantities equivalent - from the ethanol standpoint - to two cans of beer a day (35 g of alcohol/day);~* History of substance abuse or dependence;~* Patients with severe co-morbidities (at the investigator's opinion);~* Presence of liver disorders, cirrhosis or liver failure;~* Presence of psychiatric disorders diagnosed at the adult life or currently under treatment;~* Pregnant and breastfeeding women and women who want to become pregnant during the study period and who refuse to use a proper contraceptive methods during the study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- eszopiclone 3 mg (Type: EXPERIMENTAL): Eszopiclone - once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
- zopiclone 7,5mg (Type: ACTIVE_COMPARATOR): Zopiclone once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Bleeding-Model Clinical Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Be at least 18 years of age;~* Provide written informed consent prior to participation and be given a signed copy of the informed consent form;~* Be in general good health as determined by the Investigator based on a review of the health history/update for participation in the trial;~* Have at least 20 gradable teeth;~* Have established gingivitis with ≥10 % bleeding sites;~* Agree to return for scheduled visits and follow the study procedures;~* Agree to refrain from use of any non-study oral hygiene products for the duration of the study;~* Agree to delay any elective dentistry, including dental prophylaxis, until the completion of the study.~Exclusion Criteria:~* Having taken medications (antibiotic, anti-inflammatory, or anti-coagulant) which could alter gingival bleeding within 4 weeks of the Baseline Visit;~* Having any oral conditions that could interfere with study compliance and/or examination procedures, such as widespread caries, soft or hard tissue tumor of the oral cavity, or advanced periodontal disease;~* Having known hypersensitivity to the test products;~* Having removable oral appliances;~* Having fixed facial or lingual orthodontic appliances;~* Self-reported pregnancy or lactation;~* Having any diseases or condition that might interfere with the safe participation in the study;~* Having an inability to undergo study procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Positive Control (Type: ACTIVE_COMPARATOR): 2 brushings per day (AM and PM)
- Negative Control (Type: SHAM_COMPARATOR): 2 brushings per day (AM and PM)
- Experimental Control (Type: EXPERIMENTAL): Brush with Positive control in the morning and negative control in the evening

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Nutritional Supplementation on Protein and Energy Homeostasis in Malnourished Chronic Hemodialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* On hemodialysis for more than 6 months, on a thrice weekly hemodialysis program;~* Adequately dialyzed (Kt/V \> 1.4).~Exclusion Criteria:~* Patients unable to perform exercise.~* Pregnant women.~* Severe unstable underlying disease besides commonly associated with ESRD. Cardiac patients that are stable will be included.~* Patients hospitalized within the last month prior to the study.~* Patients with recirculation detected on the AV graft.~* Patients receiving steroids and/or other immunosuppressive agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): nutrition supplementation, recombinant human growth hormone, and exercise
- 2 (Type: ACTIVE_COMPARATOR): nutrition supplementation only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy males and females between 18 and 55 years (inclusive) of age.~* Non-smoking (by declaration) for a period of at least 6 months.~* Subjects able to adhere to the visit schedule and protocol requirements and be available to complete the study.~* Haematology and Chemistry values within normal ranges or with no clinical significance~* Subjects who provide written informed consent to participate in the study~Exclusion Criteria:~* Known history of significant medical disorder, which in the investigator's judgment contraindicates administration of the study medications.~* Ongoing flu symptoms or influenza~* Any clinically significant abnormality upon physical examination or in the clinical laboratory test at screening visit.~* Treatment with immune immunosuppressant drugs or other immune enhancing drugs.~* Subjects who have been immunized with anti-influenza vaccine or infected by influenza virus within one year prior to the screening visit.~* Administration of any vaccine 30 days before the screening visit.~* Known history of drug or alcohol abuse.~* Known history of HIV, hepatitis C or B virus (HCV or HBV)~* Subjects with known Guillain Barré Syndrome in the past~* 2 or more hospitalization within the last year prior to screening visit~* Increased liver enzymes 2.5 times above the upper reference level~* Known hypersensitivity and/or allergy to any drugs~* Any acute medical situation (e.g. acute infection) within 48 hours of study start, which is considered of significance by the Principal Investigator.~* Subjects who participated in another clinical study within 30 days prior to study entry~* Subjects who are non-cooperative or unwilling to sign consent form.~* Pregnant or lactating women at entry to study and those that are unwilling to agree to continue precautions for two months after completion of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- Multimeric-001 250 Mcg (Type: EXPERIMENTAL): Multimeric-001 250 Mcg in PBS
- Adjuvanted Multimeric-001 250 Mcg (Type: EXPERIMENTAL): 250 Mcg in montanide
- Phosphate Buffered saline (Type: PLACEBO_COMPARATOR): Non-adjuvanted placebo
- Adjuvanted PBS (Type: PLACEBO_COMPARATOR): Adjuvant was montanide
- Multimeric-001 500 Mcg (Type: EXPERIMENTAL): Multimeric-001 in PBS
- Adjuvanted Multimeric-001 500 Mcg (Type: EXPERIMENTAL): Adjuvant was montanide
- Multimeric-001 125 Mcg (Type: EXPERIMENTAL): Multimeric-001 in PBS

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete